US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Astellas Pharma, Inc.

15.74

+0.24001.55%

Volume:71.47K

Turnover:1.12M

Market Cap:28.18B

PE:211.70

High:16.19

Open:15.16

Low:15.16

Close:15.50

52wk High:16.19

52wk Low:8.37

Shares:1.79B

Float Shares:1.75B

Volume Ratio:0.33

T/O Rate:0.00%

Dividend:0.51

Dividend Rate:3.26%

EPS(TTM):0.0744

EPS(LYR):0.0628

ROE:7.95%

ROA:6.68%

PB:2.75

PE(LYR):250.47

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Merck, Pfizer, Astellas Drug Combo Succeeds in 2nd Phase 3 Bladder Cancer Study

FDA Approves Merck's Keytruda with Astellas's Padcev to Treat Bladder Cancer

Astellas, Pfizer announces results from Phase 3 EV-303 trial for PADCEV

Yomiuri: Astellas Pharma Offers Leadership Training to Assist Patient Group Activities

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALPMY"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALPMY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","market":"US","secType":"STK","nameCN":"Astellas Pharma, Inc.","latestPrice":15.74,"timestamp":1770411600000,"preClose":15.5,"halted":0,"volume":71467,"delay":15,"changeRate":0.01548387096774195,"floatShares":1745183156,"shares":1790310070,"eps":0.074352,"marketStatus":"Market Closed","change":0.24,"latestTime":"02-06 16:00:00 EST Delay","open":15.16,"high":16.19,"low":15.16,"amount":1119673.5487000013,"amplitude":0.066452,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.074352,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":1,"exchange":"PINK LIMITED","adjPreClose":15.5,"volumeRatio":0.332744},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","floatShares":1745183156,"roa":"6.68%","roe":"7.95%","lyrEps":0.062841,"volumeRatio":0.332744,"shares":1790310070,"dividePrice":0.5134,"high":16.19,"amplitude":0.066452,"preClose":15.5,"low":15.16,"week52Low":8.37,"pbRate":"2.75","psRate":"2.21","week52High":16.19,"institutionHeld":0,"latestPrice":15.74,"eps":0.074352,"divideRate":0.032618,"volume":71467,"delay":15,"ttmEps":0.074352,"open":15.16,"prevYearClose":13.29,"prevWeekClose":13.86,"prevMonthClose":13.86,"prevQuarterClose":13.29},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALPMY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-04","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1738645200000,"reportTimeType":"","actualEps":null},{"date":"2024-08-01","symbol":"ALPMY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722499200000,"name":null,"time":"","dateTimestamp":1722484800000,"actualEps":null},{"market":"US","date":"2024-04-25","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-02-05","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1707109200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2023-11-01","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1698811200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALPMY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALPMY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1758171600000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALPMY\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592971859","title":"Merck, Pfizer, Astellas Drug Combo Succeeds in 2nd Phase 3 Bladder Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2592971859","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592971859?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:38","pubTimestamp":1765975080,"startTime":"0","endTime":"0","summary":"A cancer-drug combination from Merck, Pfizer and Astellas Pharma has hit its goal in a second late-stage study in patients with a hard-to-treat form of bladder cancer.The companies on Wednesday said Merck's Keytruda coupled with Padcev from Pfizer and Astellas showed significantly improved survival for patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.The study met its primary endpoint, demonstrating clinically meaningful and statistically significant improvements in event-free survival, as well as in overall survival, a key secondary endpoint, the companies said.Merck, Pfizer and Astellas, which in August reported similar results from a Phase 3 study of the combination in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy, said they plan to discuss the study results with global health authorities for potential regulatory filings.Merck in 2019 inked a deal to evaluate the combination of its block","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","SG9999011175.SGD","LU1929549753.HKD","LU0122379950.USD","LU1571399168.USD","LU0106261372.USD","LU0320765489.SGD","LU0980610538.SGD","LU0306806265.USD","LU1162221912.USD","LU0456855351.SGD","LU0985320562.USD","LU1989771016.USD","PFE","SG9999002224.SGD","IE00BJJMRZ35.SGD","LU2023250843.SGD","LU0098860793.USD","IE0002141913.USD","IE00BN8TJ469.HKD","LU1894683264.USD","LU1430594728.SGD","LU0306807586.USD","BK4550","SG9999014559.SGD","LU0265550359.USD","LU1894683348.USD","LU2361044949.HKD","SG9999001440.SGD","MRK","LU1291159041.SGD","BK4592","SG9999014542.SGD","LU1035773651.USD","LU1989772840.SGD","LU0321505439.SGD","LU0006306889.USD","LU1201861249.SGD","LU1983299246.USD","BK4588","IE00B19Z3B42.SGD","LU0289739699.SGD","LU0130517989.USD","ALPMY","SG9999003800.SGD","LU1057294990.SGD","LU0130102774.USD","LU0868494617.USD","LU2361045086.USD","LU0985481810.HKD","LU2112291526.USD","LU0238689110.USD","LU2468319806.SGD","LU1066053197.SGD","LU1116320737.USD","LU1974910355.USD","LU1941712348.USD","SG9999002232.USD","LU2361044865.SGD","IE00BBT3K403.USD","LU1934455277.USD","IE00BLSP4452.SGD","IE00BJT1NW94.SGD","IE00B1BXHZ80.USD","BK4534","LU1699723380.USD","LU1066051811.HKD","LU0321505868.SGD","LU0965509010.AUD","BK4007","LU1066051498.USD","LU1116320901.HKD","SG9999015341.SGD","LU1989772923.USD","BK4516","BK4599","LU1934455863.HKD","SG9999014575.USD","BK4533","LU1883839398.USD","LU0965508806.USD","LU0225771236.USD","IE00B2B36J28.USD","LU0265550946.USD","LU0211331839.USD","LU1934455194.USD","LU1941712264.USD","IE000M9KFDE8.USD","LU2461242641.AUD","BK4581","IE00B19Z3581.USD","LU1037948541.HKD","IE00BFTCPJ56.SGD","SG9999013999.USD","SG9999014567.USD","BK4568","LU0965509283.SGD","LU0320765646.SGD","LU1037948897.HKD","LU0266013472.USD","LU0648001328.SGD","LU1023059063.AUD","SGXZ57979304.SGD","LU1093756325.SGD","LU2360032135.SGD","IE00B4R5TH58.HKD","LU0477156953.USD","SG9999001176.USD","LU1093756168.USD","BK4585","LU0058720904.USD","IE00BLSP4239.USD","LU2106854487.HKD","LU2324357040.USD","LU1917777945.USD","LU2023250504.SGD","SG9999001176.SGD","SG9999015358.SGD","LU2125154935.USD","LU0234572021.USD","IE0002270589.USD","LU0965509101.SGD","BK4559","LU0070302665.USD","LU2089984988.USD","LU2125154778.USD","LU0203347892.USD","LU1069347547.HKD","IE0009355771.USD","LU0861579265.USD","LU1066051225.USD","LU0170899867.USD","IE00BSNM7G36.USD","LU0203345920.USD","LU0225284248.USD","LU1585245621.USD","LU0208291251.USD"],"gpt_icon":1},{"id":"2585622140","title":"FDA Approves Merck's Keytruda with Astellas's Padcev to Treat Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2585622140","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585622140?lang=en_us&edition=fundamental","pubTime":"2025-11-22 01:52","pubTimestamp":1763747520,"startTime":"0","endTime":"0","summary":"The Food and Drug Administration approved Merck's Keytruda in combination with Astellas's Padcev to treat certain adults with muscle invasive bladder cancer .The FDA said Friday it has approved the drug combination as a treatment for before and after bladder-removal surgery in adult MIBC patients who are ineligible for cisplatin, a chemotherapy medication.A recent trial demonstrated statistically significant improvements in event-free survival and overall survival for patients with previously untreated MIBC who were treated with the drug combination before and after bladder-removal surgery and pelvic lymph node dissection, compared with surgery alone, the FDA said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","ALPMY","LU1037948897.HKD","LU1989772840.SGD","LU0234572021.USD","IE00BJT1NW94.SGD","LU1291159041.SGD","SG9999015341.SGD","IE000M9KFDE8.USD","LU1983299246.USD","LU2089984988.USD","BK4585","SG9999002224.SGD","LU2023250504.SGD","LU0861579265.USD","SG9999001440.SGD","LU0203345920.USD","IE00BFTCPJ56.SGD","LU1093756168.USD","LU1699723380.USD","LU2461242641.AUD","SG9999014567.USD","LU0265550946.USD","IE0009355771.USD","LU2468319806.SGD","LU2324357040.USD","IE00BBT3K403.USD","LU1571399168.USD","IE00BLSP4239.USD","LU0320765489.SGD","LU1066051811.HKD","LU1941712264.USD","LU1116320901.HKD","LU2106854487.HKD","SG9999001176.USD","LU1974910355.USD","SG9999015358.SGD","IE00B4R5TH58.HKD","LU1989771016.USD","BK4516","LU0238689110.USD","LU1929549753.HKD","MRK","SGXZ57979304.SGD","LU0965509283.SGD","LU1035773651.USD","IE0002141913.USD","BK4533","LU0208291251.USD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2576176006","title":"Astellas, Pfizer announces results from Phase 3 EV-303 trial for PADCEV","url":"https://stock-news.laohu8.com/highlight/detail?id=2576176006","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576176006?lang=en_us&edition=fundamental","pubTime":"2025-10-20 05:20","pubTimestamp":1760908807,"startTime":"0","endTime":"0","summary":"Astellas Pharma (ALPMY) and Pfizer (PFE) announced positive results from the Phase 3 EV-303 clinical trial for PADCEV, a Nectin-4 directed antibody...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astellas-pfizer-announces-results-from-phase-3-ev-303-trial-for-padcev-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astellas-pfizer-announces-results-from-phase-3-ev-303-trial-for-padcev-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0234572021.USD","BK4592","IE00B19Z3581.USD","LU0985481810.HKD","IE00BLSP4452.SGD","LU1066053197.SGD","LU0170899867.USD","LU0289739699.SGD","LU0456855351.SGD","BK4534","SG9999011175.SGD","IE0002270589.USD","IE000M9KFDE8.USD","SG9999002224.SGD","LU1894683264.USD","BK4007","ALPMY","LU0306806265.USD","SG9999013999.USD","LU1894683348.USD","IE00B19Z3B42.SGD","LU0122379950.USD","BK4585","SG9999001176.SGD","SG9999002232.USD","BK4588","PFE","LU0225284248.USD","BK4550","LU0058720904.USD","IE00BLSP4239.USD","LU1883839398.USD","SG9999003800.SGD","LU0321505439.SGD","IE00BBT3K403.USD","LU1066051498.USD","LU0868494617.USD","SG9999001176.USD","LU1023059063.AUD","LU1057294990.SGD","BK4533","LU0306807586.USD","LU0321505868.SGD","BK4568","SGXZ57979304.SGD","LU0225771236.USD","BK4599","BK4581"],"gpt_icon":0},{"id":"2575263346","title":"Yomiuri: Astellas Pharma Offers Leadership Training to Assist Patient Group Activities","url":"https://stock-news.laohu8.com/highlight/detail?id=2575263346","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575263346?lang=en_us&edition=fundamental","pubTime":"2025-10-14 14:19","pubTimestamp":1760422740,"startTime":"0","endTime":"0","summary":"Major Japanese pharmaceutical firm Astellas Pharma Inc. in Tokyo is offering unique training to support the development of personnel involved in patient group management to establish stable organizational foundations and sustain their activities.In fiscal 2021, it launched the leadership training program to equip participants with the knowledge and skills necessary for management. Participants can attend five free lectures per year, given by external instructors such as university faculty and human resource development consultants.The lectures cover topics like enhancing communication skills and approaches to organizational management. Over the past four events, a total of 72 participants from 51 groups have attended. This has led to tangible outcomes, such as participants presenting their activities at academic conferences gathering domestic specialist physicians and establishing connections with overseas patient groups.This article is from The Yomiuri Shimbun. Neither Dow Jones Newsw","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALPMY"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ALPMY\",params:#limit:6,delay:false,,,undefined,":[]}}